Emavusertib (CA-4948)

About Curis

Curis, Inc. is a U.S.-based, publicly traded oncology biotech with a mission to slow, prevent, or cure cancer by prolonging life. Its primary achievement is a strategic collaboration with Roche/Genentech, which commercializes Erivedge™ for advanced basal cell carcinoma, providing a critical royalty revenue stream. The company's strategy leverages a lean, virtual model to advance a pipeline of internally discovered and in-licensed small molecule candidates, with a current focus on IRAK4 inhibition for hematologic cancers and dual HDAC/PI3K inhibition.

About Curis

Curis, Inc. is a U.S.-based, publicly traded oncology biotech with a mission to slow, prevent, or cure cancer by prolonging life. Its primary achievement is a strategic collaboration with Roche/Genentech, which commercializes Erivedge™ for advanced basal cell carcinoma, providing a critical royalty revenue stream. The company's strategy leverages a lean, virtual model to advance a pipeline of internally discovered and in-licensed small molecule candidates, with a current focus on IRAK4 inhibition for hematologic cancers and dual HDAC/PI3K inhibition.

Therapeutic Areas